Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSIRIS osimertinib rechallenge in subsequent-line EGFR-mutated NSCLC
2016-002555-17Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico G. Rodolico - San Marco
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Azienda Ospedaliero-Universitaria Policlinico G. Rodolico - San Marco. Primary endpoint: Objective response rate. Started May 2021; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-002555-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002555-17.